SCHEMBL23610945

SCHEMBL23610945

NCCCCNC(=O)C(CCCN)NC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.60
SIRT6 Q8N6T7 1/20 0.60
TLR2 O60603 1/20 0.47
GNAI3 P08754 1/20 0.46
GNAO1 P09471 1/20 0.46
GNAI1 P63096 1/20 0.46
NMT2 O60551 2/20 0.45
NMT1 P30419 2/20 0.45
GRIN1 Q05586 2/20 0.44
GRIN2A Q12879 2/20 0.44
CPB1 P15086 1/20 0.43
CPB2 Q96IY4 1/20 0.43
PAOX Q6QHF9 2/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
DPP7 Q9UHL4 1/20 0.42
CHRNA1 P02708 2/20 0.42
CHRNG P07510 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610946 0.93 SIRT1 (0.57) SIRT1SIRT6TLR2GNAI3GNAO1
SCHEMBL19839612 0.88 SIRT1 (0.80) SIRT1SIRT6TLR2GNAI3GNAO1
SCHEMBL19839611 0.88 SIRT1 (0.80) SIRT1SIRT6TLR2GNAI3GNAO1
SCHEMBL25386549 0.81 SIRT1 (0.49) SIRT1SIRT6TLR2GRIN1GRIN2A
SCHEMBL19839576 0.81 SIRT1 (0.69) SIRT1SIRT6TLR2GNAI3GNAO1
SCHEMBL19839581 0.81 SIRT1 (0.69) SIRT1SIRT6TLR2GNAI3GNAO1
SCHEMBL19839579 0.81 SIRT1 (0.69) SIRT1SIRT6TLR2GNAI3GNAO1
Hydrochloric Acid SCHEMBL19839873 0.80 SIRT1 (0.67) SIRT1SIRT6TLR2GNAI3GNAO1
Hydrochloric Acid SCHEMBL19839877 0.80 SIRT1 (0.67) SIRT1SIRT6TLR2GNAI3GNAO1
SCHEMBL20705144 0.79 MMP1 (0.45) SIRT1SIRT6NMT2NMT1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655210-B2 Compound for improving L-arginine bioavailability THE GENERAL HOSPITAL CORPORATION (US) 2023-05-23 US disclosed
US-20210206717-A1 Compound for Improving L-Arginine Bioavailability THE GENERAL HOSPITAL CORPORATION 2021-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206717-A1 Compound for Improving L-Arginine Bioavailability ARG1, ARG2, NOS2 SIRT1 84/4885SIRT6 117/4885TLR2 4242/4885
US-11655210-B2 Compound for improving L-arginine bioavailability ARG1, ARG2, NOS2 SIRT1 84/4885SIRT6 117/4885TLR2 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.